Yuhan Strikes Long-Awaited Lung Cancer Deal Through Huge Janssen Alliance
Executive Summary
Yuhan inks long-awaited, major global license agreement for its novel third-generation EGFR TKI with Janssen, in a $1.2bn deal poised to boost the South Korean firm's ongoing R&D efforts in key therapeutic areas, while Janssen will further beef up its oncology portfolio. But competition with entrenched rival Tagrisso awaits.
You may also be interested in...
Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?
The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.
World-First Nod For Yuhan's Lung Cancer Drug, In Korea
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
Janssen’s Amivantamab Combo Shows Promise In First-Line NSCLC
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.